Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMS NASDAQ:EPIX NASDAQ:GNPX NASDAQ:MNPR NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AEPIXESSA Pharma$0.20$0.46$0.18▼$6.45$9.52M1.572.99 million shsN/AGNPXGenprex$9.16-16.4%$11.32$7.00▼$149.50$8.34M-0.71237,511 shs5.63 million shsMNPRMonopar Therapeutics$81.29+2.5%$61.84$4.87▼$105.00$501.56M1.4245,929 shs63,440 shsSCYXSCYNEXIS$0.77-1.3%$0.89$0.66▼$1.49$32.28M1.68236,429 shs434,886 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma0.00%0.00%-7.28%-89.24%-96.49%GNPXGenprex-4.70%-73.90%-4.70%-23.22%-93.89%MNPRMonopar Therapeutics+2.11%-12.31%+24.55%+69.35%+1,410.29%SCYXSCYNEXIS0.00%-3.70%-29.09%+5.69%-46.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AEPIXESSA Pharma$0.20$0.46$0.18▼$6.45$9.52M1.572.99 million shsN/AGNPXGenprex$9.16-16.4%$11.32$7.00▼$149.50$8.34M-0.71237,511 shs5.63 million shsMNPRMonopar Therapeutics$81.29+2.5%$61.84$4.87▼$105.00$501.56M1.4245,929 shs63,440 shsSCYXSCYNEXIS$0.77-1.3%$0.89$0.66▼$1.49$32.28M1.68236,429 shs434,886 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma0.00%0.00%-7.28%-89.24%-96.49%GNPXGenprex-4.70%-73.90%-4.70%-23.22%-93.89%MNPRMonopar Therapeutics+2.11%-12.31%+24.55%+69.35%+1,410.29%SCYXSCYNEXIS0.00%-3.70%-29.09%+5.69%-46.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/AEPIXESSA Pharma 1.75Reduce$2.00894.04% UpsideGNPXGenprex 1.00SellN/AN/AMNPRMonopar Therapeutics 3.00Buy$105.6729.99% UpsideSCYXSCYNEXIS 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCYX, MNPR, GNPX, EPIX, and ADMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025SCYXSCYNEXISWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$125.0010/13/2025MNPRMonopar TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$125.0010/10/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025EPIXESSA PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GNPXGenprexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MNPRMonopar TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$80.00 ➝ $142.0010/2/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$77.00 ➝ $115.009/29/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$70.00 ➝ $105.009/27/2025EPIXESSA PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AGNPXGenprexN/AN/AN/AN/A$7.46 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ASCYXSCYNEXIS$3.75M8.61N/AN/A$1.45 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AEPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%12/16/2025 (Estimated)GNPXGenprex-$21.11MN/A0.00N/AN/AN/A-809.27%-386.95%11/12/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.40N/A15.40N/A-599.05%-43.04%-28.21%11/5/2025 (Estimated)Latest SCYX, MNPR, GNPX, EPIX, and ADMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025MNPRMonopar Therapeutics-$0.48N/AN/AN/AN/AN/A11/5/2025Q3 2025SCYXSCYNEXIS-$0.21N/AN/AN/AN/AN/A8/14/2025Q2 2025GNPXGenprex-$35.50-$8.50+$27.00-$0.17N/AN/A8/13/2025Q3 2025EPIXESSA Pharma-$0.17-$0.09+$0.08-$0.09N/AN/A8/13/2025Q2 2025SCYXSCYNEXIS-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 million8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69839.96%N/AN/A N/AGNPXGenprexN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ALatest SCYX, MNPR, GNPX, EPIX, and ADMS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17EPIXESSA PharmaN/A69.0669.06GNPXGenprexN/A0.840.84MNPRMonopar TherapeuticsN/A33.9333.93SCYXSCYNEXISN/A5.205.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%EPIXESSA Pharma75.12%GNPXGenprex14.05%MNPRMonopar Therapeutics1.83%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%EPIXESSA Pharma15.50%GNPXGenprex0.44%MNPRMonopar Therapeutics20.50%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableEPIXESSA Pharma5047.31 million39.98 millionOptionableGNPXGenprex20910,000907,000No DataMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableSCYXSCYNEXIS6041.92 million39.89 millionOptionableSCYX, MNPR, GNPX, EPIX, and ADMS HeadlinesRecent News About These CompaniesSCYNEXIS (NASDAQ:SCYX) Earns "Sell (E+)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comSCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study TerminationOctober 15, 2025 | quiverquant.comQSCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO StudyOctober 15, 2025 | globenewswire.comSCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)September 30, 2025 | markets.businessinsider.comScynexis announces presentations highlighting data on SCY-247September 4, 2025 | msn.comSCYNEXIS to Present Promising Data on SCY-247's Antifungal Activity at TIMM-12 CongressSeptember 4, 2025 | quiverquant.comQSCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)September 4, 2025 | globenewswire.comSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025August 25, 2025 | markets.businessinsider.comScynexis reports Q2 EPS (14c), consensus (19c)August 14, 2025 | msn.comSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deSCYNEXIS Reports Improved Financials Amidst Strategic DevelopmentsAugust 14, 2025 | msn.comSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comSCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis TreatmentAugust 8, 2025 | msn.comSCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSKMay 30, 2025 | nasdaq.comSCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA HoldMay 28, 2025 | insidermonkey.comSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyMay 28, 2025 | globenewswire.comSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finance.yahoo.comScynexis to present preclinical data on SCY-247 at ESCMID MeetingApril 9, 2025 | markets.businessinsider.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCYX, MNPR, GNPX, EPIX, and ADMS Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.ESSA Pharma NASDAQ:EPIX$0.20 0.00 (0.00%) As of 10/13/2025ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Genprex NASDAQ:GNPX$9.16 -1.80 (-16.42%) Closing price 04:00 PM EasternExtended Trading$9.20 +0.04 (+0.46%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Monopar Therapeutics NASDAQ:MNPR$81.29 +2.00 (+2.52%) Closing price 04:00 PM EasternExtended Trading$90.64 +9.35 (+11.50%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.SCYNEXIS NASDAQ:SCYX$0.77 -0.01 (-1.28%) Closing price 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.04%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
